Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review)
- Authors:
- Jianwei Xu
- Hanxiang Zhan
- Feng Li
- Sanyuan Hu
- Lei Wang
-
Affiliations: School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Pancreatic Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China - Published online on: February 18, 2021 https://doi.org/10.3892/or.2021.7977
- Article Number: 26
This article is mentioned in:
Abstract
|
Heinrich S and Lang H: Neoadjuvant therapy of pancreatic cancer: Definitions and benefits. Int J Mol Sci. 18:16222017. View Article : Google Scholar | |
|
Cassinotto C, Sa-Cunha A and Trillaud H: Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging. 97:1225–1232. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, et al: Importance of Normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann surg. 27:740–747. 2020. View Article : Google Scholar | |
|
Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N and Zeh HJ III: Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 21:4351–4358. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al: Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, et al: Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118:5749–5756. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xia BT, Fu B, Wang J, Kim Y, Ahmad SA, Dhar VK, Levinsky NC, Hanseman DJ, Habib DA, Wilson GC, et al: Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol. 115:376–383. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et al: Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101. JAMA Surg. 151:e1611372016. View Article : Google Scholar : PubMed/NCBI | |
|
Raman SP, Horton KM and Fishman EK: Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 18:511–522. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Donahue TR, Isacoff WH, Hines OJ, Tomlinson JS, Farrell JJ, Bhat YM, Garon E, Clerkin B and Reber HA: Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: Influence on patient selection for surgery. Arch Surg. 146:836–843. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hartman DJ and Krasinskas AM: Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 136:100–109. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dholakia AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P, Laheru DA, Zheng L, De Jesus-Acosta A, Le DT, et al: Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. J Radiat Oncol. 2:413–425. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hackert T, Strobel O, Michalski CW, Mihaljevic AL, Mehrabi A, Müller-Stich B, Berchtold C, Ulrich A and Büchler MW: The TRIANGLE operation-radical surgery after neoadjuvant treatment for advanced pancreatic cancer: A single arm observational study. HPB (Oxford). 19:1001–1007. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Klaiber U, Mihaljevic A and Hackert T: Radical pancreatic cancer surgery-with arterial resection. Transl Gastroenterol Hepatol. 4:82019. View Article : Google Scholar : PubMed/NCBI | |
|
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Okada K, Takahashi S and Sueda T: Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. Cancer Chemother Pharmacol. 79:801–811. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Reni M, Zanon S, Balzano G, Nobile S, Pircher CC, Chiaravalli M, Passoni P, Arcidiacono PG, Nicoletti R, Crippa S, et al: Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 28:2786–2792. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW and Debus J: Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 21:2801–2807. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, et al: New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 18:971–976. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nasief H, Hall W, Zheng C, Tsai S, Wang L, Erickson B and Li XA: Improving treatment response prediction for chemoradiation therapy of pancreatic cancer using a combination of delta-radiomics and the clinical biomarker CA19-9. Front Oncol. 9:14642019. View Article : Google Scholar : PubMed/NCBI | |
|
Payen T, Oberstein PE, Saharkhiz N, Palermo CF, Sastra SA, Han Y, Nabavizadeh A, Sagalovskiy IR, Orelli B, Rosario V, et al: Harmonic motion imaging of pancreatic tumor stiffness indicates disease state and treatment response. Clin Cancer Res. 26:1297–1308. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Farren MR, Sayegh L, Ware MB, Chen HR, Gong J, Liang Y, Krasinskas A, Maithel SK, Zaidi M, Sarmiento JM, et al: Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI Insight. 5:e1303622020. View Article : Google Scholar | |
|
Ehrlich D, Ather N, Rahal H, Donahue TR, Hines OJ, Kim S, Sedarat A, Muthusamy VR and Watson R: The Utility of EUS-FNA to determine surgical candidacy in patients with pancreatic cancer after neoadjuvant therapy. J Gastrointest Surg. 24:2807–2813. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, Hogg ME, Lotze M, et al: Assessment of response to neoadjuvant therapy using CT texture analysis in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. AJR Am J Roentgenol. 214:362–369. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, Zeh HJ III, Zureikat AH and Boone BA: Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 27:898–906. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mota Reyes C, Teller S, Muckenhuber A, Konukiewitz B, Safak O, Weichert W, Friess H, Ceyhan GO and Demir IE: Neoadjuvant therapy remodels the pancreatic cancer microenvironment via depletion of protumorigenic immune cells. Clin Cancer Res. 26:220–231. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW and Hackert T: Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford). 22:224–232. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kuwabara S, Tsuchikawa T, Nakamura T, Hatanaka Y, Hatanaka KC, Sasaki K, Ono M, Umemoto K, Suzuki T, Sato O, et al: Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Cancer Sci. 110:1853–1862. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, et al: Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 273:341–349. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, et al: Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: A multicenter case-control study of 240 patients. BMC Cancer. 19:2522019. View Article : Google Scholar : PubMed/NCBI | |
|
Kawai M, Hirono S, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, Kobayashi R, Ueno M, Hayami S, Tanioka K and Yamaue H: Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Surgery. 165:1151–1160. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, et al: Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 156:108–118.e4. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gemenetzis G, Groot VP, Yu J, Ding D, Teinor JA, Javed AA, Wood LD, Burkhart RA, Cameron JL, Makary MA, et al: Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: Results of the prospective CLUSTER Study. Ann Surg. 268:408–420. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, et al: A phase ii clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Ann Surg. 268:610–619. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim BR, Kim JH, Ahn SJ, Joo I, Choi SY, Park SJ and Han JK: CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol. 29:362–372. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Klaassen R, Gurney-Champion OJ, Engelbrecht MRW, Stoker J, Wilmink JW, Besselink MG, Bel A, van Tienhoven G, van Laarhoven HWM and Nederveen AJ: Evaluation of six diffusion-weighted MRI models for assessing effects of neoadjuvant chemoradiation in pancreatic cancer patients. Int J Radiat Oncol Biol Phys. 102:1052–1062. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
van Veldhuisen E, Vogel JA, Klompmaker S, Busch OR, van Laarhoven HWM, van Lienden KP, Wilmink JW, Marsman HA and Besselink MG: Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB (Oxford). 20:605–611. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dalah E, Erickson B, Oshima K, Schott D, Hall WA, Paulson E, Tai A, Knechtges P and Li XA: Correlation of ADC with pathological treatment response for radiation therapy of pancreatic cancer. Transl Oncol. 11:391–398. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, et al: Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 124:1701–1709. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, et al: Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 25:1432–1439. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, et al: Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Sur. 269:733–740. 2019. View Article : Google Scholar | |
|
Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Wörner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, et al: Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma. Sci Rep. 7:170382017. View Article : Google Scholar : PubMed/NCBI | |
|
Sherman WH, Hecht E, Leung D and Chu K: Predictors of response and survival in locally advanced adenocarcinoma of the pancreas following neoadjuvant GTX with or without radiation therapy. Oncologist. 23:4–e10. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Felix K, Hinz U, Dobiasch S, Hackert T, Bergmann F, Neumüller M, Gronowitz S, Bergqvist M and Strobel O: Preoperative serum thymidine kinase activity as novel monitoring, prognostic, and predictive biomarker in pancreatic cancer. Pancreas. 47:72–79. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, Bernard DW, Li Y, Yokoi K, Katz MH, et al: Nanoplasmonic quantification of tumor-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring. Nat Biomed Eng. 1:00212017. View Article : Google Scholar : PubMed/NCBI | |
|
Sakane M, Tatsumi M, Hori M, Onishi H, Tsuboyama T, Nakamoto A, Ota T, Eguchi H, Wakasa K, Hatazawa J and Tomiyama N: Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma. Eur J Radiol. 94:64–69. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yabushita Y, Mori R, Taniguchi K, Matsuyama R, Kumamoto T, Sakamaki K, Kubota K and Endo I: Combined analyses of hENT1, TS, and DPD predict outcomes of borderline-resectable pancreatic cancer. Anticancer Res. 37:2465–2476. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Akita H, Takahashi H, Ohigashi H, Tomokuni A, Kobayashi S, Sugimura K, Miyoshi N, Moon JH, Yasui M, Omori T, et al: FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol. 43:1061–1067. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Okada KI, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Hayami S, Kojima F and Yamaue H: Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma. J Hepatobiliary Pancreat Sci. 24:161–168. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O and Bachet JB: CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 27:3104–3116. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ and Hoffe SE: Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 56:391–397. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, Maitra A, Wang H, Tian W, Taguchi A and Hanash SM: Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 107:djv1322015. View Article : Google Scholar : PubMed/NCBI | |
|
Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB and Tsai S: Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford). 17:942–952. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hasegawa S, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K, Kobayashi S, Marubashi S, et al: Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. Oncol Lett. 11:1560–1566. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA and Donahue TR: CA19-9 normalization during pre-operative treatment predicts longer survival for patients with locally progressed pancreatic cancer. J Gastrointest Surg. 20:1331–1342. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Delbeke D and Martin WH: PET and PET/CT for pancreatic malignancies. Surg Oncol Clin N Am. 19:235–254. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, et al: Role of repeat 18F-fluorodeoxyglucose positron emission tomography examination in predicting pathologic response following neoadjuvant chemoradiotherapy for esophageal adenocarcinoma. JAMA Surg. 150:555–562. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A and Brunotte F: Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer. Clin Cancer Res. 21:5460–5468. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, et al: Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 27:648–653. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Miyata T, Kamata K and Takenaka M: Endoscopic ultrasonography-guided transenteric pancreatic duct drainage without cautery for obstructive pancreatitis as a result of ampullary carcinoma. Dig Endosc. 30:403–404. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenthal MH, Lee A and Jajoo K: Imaging and endoscopic approaches to pancreatic cancer. Hematol Oncol Clin North Am. 29:675–699. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Barreto SG, Loveday B, Windsor JA and Pandanaboyana S: Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J Surg. 89:481–487. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shi S, Liang C, Xu J, Meng Q, Hua J, Yang X, Ni Q and Yu X: The strain ratio as obtained by endoscopic ultrasonography elastography correlates with the stroma proportion and the prognosis of local pancreatic cancer. Ann Surg. 271:559–565. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, et al: Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bettini N, Moutardier V, Turrini O, Bories E, Monges G, Giovannini M and Delpero JR: Preoperative locoregional re-evaluation by endoscopic ultrasound in pancreatic ductal adenocarcinoma after neoadjuvant chemoradiation. Gastroenterol Clin Biol. 29:659–663. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Baliyan V, Kordbacheh H, Parakh A and Kambadakone A: Response assessment in pancreatic ductal adenocarcinoma: Role of imaging. Abdom Radiol (NY). 43:435–444. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, et al: A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 7:644–649. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Granata V, Fusco R, Setola SV, Piccirillo M, Leongito M, Palaia R, Granata F, Lastoria S, Izzo F and Petrillo A: Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J Gastroenterol. 23:4767–4778. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, et al: Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 69:127–157. 2019.PubMed/NCBI | |
|
Fazal MI, Patel ME, Tye J and Gupta Y: The past, present and future role of artificial intelligence in imaging. Eur J Radiol. 105:246–250. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rajkomar A, Dean J and Kohane I: Machine learning in medicine. N Engl J Med. 380:1347–1358. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kantarjian H and Yu PP: Artificial intelligence, big data, and cancer. JAMA Oncology. 1:573–574. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chu LC, Goggins MG and Fishman EK: Diagnosis and detection of pancreatic cancer. Cancer J. 23:333–342. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, Sun K, Li L, Li B, Wang M and Tian J: The applications of radiomics in precision diagnosis and treatment of oncology: Opportunities and challenges. Theranostics. 9:1303–1322. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Parekh VS and Jacobs MA: Deep learning and radiomics in precision medicine. Expert Rev Precis Med Drug Dev. 4:59–72. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, et al: Predicting response to cancer immunotherapy using non-invasive radiomic biomarkers. Ann Oncol. 30:998–1004. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Juiz NA, Iovanna J and Dusetti N: Pancreatic cancer heterogeneity can be explained beyond the genome. Front Oncol. 9:2462019. View Article : Google Scholar : PubMed/NCBI | |
|
Neesse A, Algul H, Tuveson DA and Gress TM: Stromal biology and therapy in pancreatic cancer: A changing paradigm. Gut. 64:1476–1484. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dougan SK: The pancreatic cancer microenvironment. Cancer J. 23:321–325. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Braman NM, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P, Plecha D and Madabhushi A: Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 19:572017. View Article : Google Scholar : PubMed/NCBI | |
|
Shu Z, Fang S, Ye Q, Mao D, Cao H, Pang P and Gong X: Prediction of efficacy of neoadjuvant chemoradiotherapy for rectal cancer: The value of texture analysis of magnetic resonance images. Abdom Radiol (NY). 44:3755–3784. 2019.PubMed/NCBI | |
|
Ypsilantis PP, Siddique M, Sohn HM, Davies A, Cook G, Goh V and Montana G: Predicting response to neoadjuvant chemotherapy with PET imaging using convolutional neural networks. PLoS One. 10:e01370362015. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty J, Langdon-Embry L, Cunanan KM, Escalon JG, Allen PJ, Lowery MA, O'Reilly EM, Gönen M, Do RG and Simpson AL: Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. PLoS One. 12:e01880222017. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Najami I, Drue HC, Steele R and Baatrup G: Dual energy CT-a possible new method to assess regression of rectal cancers after neoadjuvant treatment. J Surg Oncol. 116:984–988. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Li Y, Shi GF, Zhou T and Tan BB: The concentration of iodine in perigastric adipose tissue: A novel index for the assessment of serosal invasion in patients with gastric cancer after neoadjuvant chemotherapy. Digestion. 98:87–94. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yin Q, Zou X, Zai X, Wu Z, Wu Q, Jiang X, Chen H and Miao F: Pancreatic ductal adenocarcinoma and chronic mass-forming pancreatitis: Differentiation with dual-energy MDCT in spectral imaging mode. Eur J Radiol. 84:2470–2476. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kawamoto S, Fuld MK, Laheru D, Huang P and Fishman EK: Assessment of iodine uptake by pancreatic cancer following chemotherapy using dual-energy CT. Abdom Radiol (NY). 43:445–456. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Noda Y, Goshima S, Miyoshi T, Kawada H, Kawai N, Tanahashi Y and Matsuo M: Assessing chemotherapeutic response in pancreatic ductal adenocarcinoma: Histogram analysis of iodine concentration and CT number in single-source dual-energy CT. AJR Am J Roentgenol. 211:1221–1226. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Noid G, Tai A, Schott D, Mistry N, Liu Y, Gilat-Schmidt T, Robbins JR and Li XA: Technical Note: Enhancing soft tissue contrast and radiation-induced image changes with dual-energy CT for radiation therapy. Med Phys. Jul 4–2018.(Epub ahead of print). doi: 10.1002/mp.13083. View Article : Google Scholar : PubMed/NCBI | |
|
Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K, Liu L, Long J, Xu J, Lu R, et al: Potential biomarkers in lewis negative patients with pancreatic cancer. Ann Surg. 265:800–805. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L and Zhan HX: Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer. 141:231–241. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB and Tsai S: Poor Glycemic control is associated with failure to complete neoadjuvant therapy and surgery in patients with localized pancreatic cancer. J Gastrointest Surg. 21:496–505. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Glazer ES, Rashid OM, Pimiento JM, Hodul PJ and Malafa MP: Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Surgery. 160:1288–1293. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF and Korc M: MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res. 17:5812–5821. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Battini S, Faitot F, Imperiale A, Cicek AE, Heimburger C, Averous G, Bachellier P and Namer IJ: Metabolomics approaches in pancreatic adenocarcinoma: Tumor metabolism profiling predicts clinical outcome of patients. BMC Med. 15:562017. View Article : Google Scholar : PubMed/NCBI | |
|
Jia H, Shen X, Guan Y, Xu M, Tu J, Mo M, Xie L, Yuan J, Zhang Z, Cai S, et al: Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. Radiother Oncol. 128:548–556. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wei S, Liu L, Zhang J, Bowers J, Gowda GA, Seeger H, Fehm T, Neubauer HJ, Vogel U, Clare SE and Raftery D: Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 7:297–307. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Allen VB, Gurusamy KS, Takwoingi Y, Kalia A and Davidson BR: Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 7:Cd0093232016.PubMed/NCBI | |
|
Ta R, O'Connor DB, Sulistijo A, Chung B and Conlon KC: The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: A systematic review and meta-analysis. Dig Surg. 36:251–260. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Peng JS, Mino J, Monteiro R, Morris-Stiff G, Ali NS, Wey J, El-Hayek KM, Walsh RM and Chalikonda S: Diagnostic laparoscopy prior to neoadjuvant therapy in pancreatic cancer is high yield: An analysis of outcomes and costs. J Gastrointest Surg. 21:1420–1427. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Slaar A, Eshuis WJ, van der Gaag NA, Nio CY, Busch OR, van Gulik TM, Reitsma JB and Gouma DJ: Predicting distant metastasis in patients with suspected pancreatic and periampullary tumors for selective use of staging laparoscopy. World J Surg. 35:2528–2534. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
NCCN, . NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (version 1.2019). http://www.nccn.org | |
|
Schnelldorfer T, Gagnon AI, Birkett RT, Reynolds G, Murphy KM and Jenkins RL: Staging laparoscopy in pancreatic cancer: A potential role for advanced laparoscopic techniques. J Am Coll Surg. 218:1201–1206. 2014. View Article : Google Scholar : PubMed/NCBI |
